Efficacy and Safety of Ypeginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B

Inclusion Criteria: * Age:18\~60 years. * Pregnancy tests of female patients must be negative. All patients with effective birth control measures during treatment period and 6 months after the cessation of treatment. * Serum HBsAg positive for at least 6 months. * Serum HBeAg positive with HBV DNA ≥20,000IU/ml. * 2×ULN≤ALT≤10×ULN at screening(ULN=upper limit of normal). Exclusion Criteria: * Pregnant or lactating women. * Mental disorder or physical disability. * Interferon treatment history or using nucleos(t)ide analogue for chronic hepatitis B treatment within the previous 6 months. * WBC\<3000/mm3, or ANC \<1500/mm3, or PLT \<90,000/mm3. * Co-infection with HAV, HIV, HCV, HDV, HEV. * Both HBsAg and anti-HBs are positive, or both HBeAg and anti-HBe are positive at screening. * Chest X-ray with clinically significant active inflammatory process, history of significant pulmonary disease or any history of interstitial lung disease. * Evidence of hepatic decompensation. * History of hypothyroidism or current treatment for thyroid disease. * Uncontrolled significant chronic medical conditions other than chronic hepatitis B, or other conditions which in the opinion of the investigator preclude enrollment into the study.